Samsung Biologics has unveiled a process innovation case study demonstrating a reduction in biopharmaceutical development timelines from 13 months down to 9.5 months. The achievement highlights the company's commitment to sharpening its global competitiveness as a contract development and manufacturing organization (CDMO) by driving improvements not only in large-scale production capacity, but also in development velocity and manufacturing efficiency.
Samsung Biologics announced on September 28 that it showcased its latest biopharmaceutical process innovation strategies at BioProcess International (BPI) 2026, a premier global bioindustry conference held in Boston from September 22 to 25. The event convened approximately 250 companies and more than 3,000 global experts to share advancements in biopharmaceutical development, manufacturing, and analytics.
Marking its ninth consecutive year at BPI since 2018, Samsung Biologics hosted a standalone booth highlighting its end-to-end service capabilities spanning contract research (CRO), contract development (CDO), and contract manufacturing (CMO). Wall displays inside the booth spotlighted core competencies, including the proprietary Samsung Organoid service, differentiated CDO capabilities, and multi-modality manufacturing capabilities. The Samsung Organoid service evaluates and selects promising drug candidates by testing molecules on three-dimensional (3D) patient-derived tumor models for colorectal, lung, liver, gastric, and breast cancers.
During a presentation on September 23 titled "From Complexity to Confidence," Lee Tae-hee, Executive Director and Head of the Antibody Cell Purification Process Development Team, detailed how Samsung Biologics successfully compressed the development timeline from 13 months to 9.5 months through an integrated chemistry, manufacturing, and controls (CMC) strategy.
The company also presented technological breakthroughs during technical poster sessions. Kim Young-hee, Head of the Cell Line Development Group, introduced "A streamlined cell line development platform for complex molecules," outlining strategies for optimizing drug quality and efficacy from the earliest stages of cell line development. Meanwhile, Lee So-jung, Head of the Upstream Process Development Group, presented on "S-Tensify™," the company's proprietary upstream process enhancement platform. S-Tensify™ increases cell density during culture, doubling target protein production titers while maintaining rigorous quality standards.
"BPI provided an ideal platform to demonstrate our end-to-end capabilities spanning CRO, CDO, and CMO, alongside our differentiated technological strengths," said James Choi, Executive Vice President and Head of Sales Support at Samsung Biologics. "We will continue to solidify our position in the global bio market through advanced technologies and reliable services."
